RFA-CA-25-001-Full-Announcement.html

This Request for Applications (RFA) from the National Cancer Institute (NCI) seeks grant applications for early-stage development of innovative molecular and cellular analysis technologies for cancer research under grant number RFA-CA-25-001. The funding is offered through the Innovative Molecular Analysis Technologies (IMAT) Program and falls under CFDA 93.394 for Cancer Detection and Diagnosis Research.

The opportunity is open to a wide range of applicants including higher education institutions, nonprofits, small businesses, tribal organizations, and government entities. The focus is on developing novel technical capabilities for analyzing molecular and cellular features of cancer biology, with potential applications in cancer detection, screening, diagnosis, treatment, and epidemiology. Projects must demonstrate high technical innovation and potential to enhance cancer research or address cancer health disparities. While proposed technologies may have broad applicability, they must specifically target improvements in molecular/cellular characterization of cancer biology. The R61 grant mechanism will be used and clinical trials are not allowed under this funding opportunity.